Merck price target raised to $142 from $139 at Truist

Truist analyst Robyn Karnauskas raised the firm’s price target on Merck to $142 from $139 and keeps a Buy rating on the shares. The firm is updating its model after the company disclosed FDA approval of sotatercept for the treatment of adults with pulmonary arterial hypertension with a broad and clean label, the analyst tells investors in a research note, also boosting the FY25 EPS view on the stock by 4c to $9.72.